Flamel Technologies S.A. (Flamel) is a biopharmaceutical company. Flamel is engaged in the development and licensing of two polymer-based drug delivery technologies. Its drug delivery technology business is built primarily on two technologies: Medusa and Micropump. Its hydrogel Medusa technology is designed to provide controlled release following injection of therapeutic proteins, peptides and other large and small molecules. Its Micropump technology is a microparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking and bioavailability enhancement. In March 2012, the Company acquired, Eclat Pharmaceuticals, LLC (Eclat), through its wholly owned subsidiary Flamel US Holdings, Inc. (Flamel US). The Company has two direct wholly owned subsidiaries: Flamel US Holdings, Inc. and Flamel Technologies, Inc.